Article Text

PDF
Oral anticancer medicines in acute oncology; recognition by non-specialist clinicians and risk reduction measures
  1. Carl D Booth1,
  2. S Michael Crawford2,
  3. Ganesan Jeyasangar2,
  4. Rebecca Daykin3
  1. 1Lead Pharmacist for Cancer Services, Pharmacy Department, Airedale NHS Foundation Trust, Airedale General Hospital, Keighley, West Yorkshire, UK
  2. 2Department of Medical Oncology, Airedale NHS Foundation Trust, Keighley, UK
  3. 3Pharmacy Department, Airedale NHS Foundation Trust, Keighley, UK
  1. Correspondence to Carl D Booth, Lead Pharmacist for Cancer Services, Pharmacy Department, Airedale NHS Foundation Trust, Airedale General Hospital, Skipton Road, Steeton, Keighley, West Yorkshire, BD20 6TD, UK; carl.booth{at}anhst.nhs.uk

Abstract

Objective This study investigated the awareness of non-oncology specialist medical staff about commonly used oral anticancer medicines (OAMs).

Methods Interviews conducted with a range of non-oncology specialist doctors.

Results The recognition of OAMs was poor by all grades of doctors, with capecitabine being the only drug recognised by more than half the doctors (26 of 40; 65%). Consultant medical staff scored significantly better than most junior grades of staff.

Conclusions A barrier to safe patient care appears to be the initial identification of OAMs on acute admission. Once a drug had been identified as an OAM, doctors are aware that they should not prescribe it and should contact the acute oncology service for advice. A range of measures has been introduced to improve the identification of OAMs by doctors.

  • ONCOLOGY
  • CHEMOTHERAPY
  • MEDICAL EDUCATION & TRAINING
  • CLINICAL PHARMACY
  • PHARMACOTHERAPY

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.